Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/CAAC.21708
   PubMed Web of Science ®Google Scholar
• Cancer statistics review, 1975–2018 - SEER statistics; 2022. Available from: https://seer.cancer.gov/archive/csr/1975_2018/. Accessed September 14, 2022.
   Google Scholar
• DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–451. doi:10.3322/CAAC.21583
   PubMed Web of Science ®Google Scholar
• Shachar SS, Hurria A, Muss HB. Breast cancer in women older than 80 years. J Oncol Pract. 2016;12(2):123–132. doi:10.1200/JOP.2015.010207
   Web of Science ®Google Scholar
• Markopoulos C, van de Water W, van de Velde CJ. Breast cancer in the elderly: reducing the losses. Future Oncol. 2013;9(9):1253–1256. doi:10.2217/FON.13.120
   Web of Science ®Google Scholar
• Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061–2067. doi:10.1056/NEJM199912303412706
   PubMed Web of Science ®Google Scholar
• Smith-Graziani D, Lei X, Giordano SH, Zhao H, Karuturi M, Chavez-MacGregor M. Delayed initiation of adjuvant chemotherapy in older women with breast cancer. Cancer Med. 2020;9(19):6961–6971. doi:10.1002/CAM4.3363
   Web of Science ®Google Scholar
• Abu-Gheida I, Hammoudeh L, Abdel-Razeq H. Controversies of radiation therapy omission in elderly women with early stage invasive breast cancer. Transl Cancer Res. 2020;9(Suppl 1):S126. doi:10.21037/TCR.2019.06.47
   Web of Science ®Google Scholar
• Huang XZ, Chen Y, Chen WJ, et al. Effect of radiotherapy after breast-conserving surgery in older patients with early breast cancer and breast ductal carcinoma in situ: a meta-analysis. Oncotarget. 2017;8(17):28215. doi:10.18632/ONCOTARGET.15998
   Google Scholar
• Bouchardy C, Rapiti E, Fioretta G, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol. 2003;21(19):3580–3587. doi:10.1200/JCO.2003.02.046
   PubMed Web of Science ®Google Scholar
• Wildiers H, Kunkler I, Biganzoli L, et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol. 2007;8(12):1101–1115. doi:10.1016/S1470-2045(07)70378-9
   PubMed Web of Science ®Google Scholar
• Parks R, Cheung KL. Challenges in geriatric Oncology-A surgeon’s perspective. Curr Oncol. 2022;29(2):659–674. doi:10.3390/CURRONCOL29020058
   Web of Science ®Google Scholar
• Ward SE, Richards PD, Morgan JL, et al. Omission of surgery in older women with early breast cancer has an adverse impact on breast cancer-specific survival. Br J Surg. 2018;105(11):1454–1463. doi:10.1002/BJS.10885
   Web of Science ®Google Scholar
• Yin M, Verschraegen C, Vincent VH, Patel SM, George T, Truica CI. Impact of lack of surgery on outcomes in elderly women with nonmetastatic breast cancer-A surveillance, epidemiology, and end results 18 population based study. Medicine. 2020;99(3):e18745. doi:10.1097/MD.0000000000018745
   Web of Science ®Google Scholar
• Morgan JL, George J, Holmes G, et al. Breast cancer surgery in older women: outcomes of the Bridging Age Gap in Breast Cancer study. Br J Surg. 2020;107(11):1468–1479. doi:10.1002/BJS.11617
   Web of Science ®Google Scholar
• Morgan JL, Walters SJ, Collins K, et al. What influences healthcare professionals’ treatment preferences for older women with operable breast cancer? An application of the discrete choice experiment. Eur J Surg Oncol. 2017;43(7):1282–1287. doi:10.1016/J.EJSO.2017.01.012
   Web of Science ®Google Scholar
• Peters E, Anzeneder T, Jackisch C, et al. The treatment of primary breast cancer in older women with adjuvant therapy: a retrospective analysis of data from over 3000 patients from the PATH biobank, with two-year follow-up. Deutsches Ärzteblatt International. 2015;112(35–36):577. doi:10.3238/ARZTEBL.2015.0577
   Web of Science ®Google Scholar
• Martelli G, Miceli R, Costa A, et al. Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen: fifteen-year results of a prospective study. Cancer. 2008;112(3):481–488. doi:10.1002/CNCR.23213
   Web of Science ®Google Scholar
• Soyder A, Özbaş S, Koçak S. Locoregional recurrence and survival rates after breast-conserving surgery and hormonal therapy in 70-year-old or older patients with Stage I or IIA breast carcinoma. Breast Care. 2013;8(2):134. doi:10.1159/000350776
   Web of Science ®Google Scholar
• Mandelblatt JS, Edge SB, Meropol NJ, et al. Sequelae of axillary lymph node dissection in older women with stage 1 and 2 breast carcinoma. Cancer. 2002;95(12):2445–2454. doi:10.1002/CNCR.10983
   Web of Science ®Google Scholar
• Rudenstam CM, Zahrieh D, Forbes JF, et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10–93. J Clin Oncol. 2006;24(3):337–344. doi:10.1200/JCO.2005.01.5784
   Web of Science ®Google Scholar
• Wang Z, Wu LC, Chen JQ. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat. 2011;129(3):675–689. doi:10.1007/S10549-011-1665-1
   Web of Science ®Google Scholar
• Christian N, Heelan Gladden A, Friedman C, et al. Increasing omission of radiation therapy and sentinel node biopsy in elderly patients with early stage, hormone-positive breast cancer. Breast J. 2020;26(2):133–138. doi:10.1111/TBJ.13483
   Web of Science ®Google Scholar
• Sun J, Mathias BJ, Sun W, et al. Is it wise to omit sentinel node biopsy in elderly patients with breast cancer? Ann Surg Oncol. 2021;28(1):320–329. doi:10.1245/S10434-020-08759-1
   Web of Science ®Google Scholar
• Liang S, Hallet J, Simpson JS, Tricco AC, Scheer AS. Omission of axillary staging in elderly patients with early stage breast cancer impacts regional control but not survival: a systematic review and meta-analysis. J Geriatr Oncol. 2017;8(2):140–147. doi:10.1016/J.JGO.2016.12.003
   Web of Science ®Google Scholar
• Xu L, Wen N, Qiu J, et al. Predicting survival benefit of sparing sentinel lymph node biopsy in low-risk elderly patients with early breast cancer: a population-based analysis. Front Oncol. 2020;10:1718. doi:10.3389/FONC.2020.01718/BIBTEX
   Web of Science ®Google Scholar
• Sentinel node biopsy in breast cancer: omission of axillary clearance after macrometastases. A Randomized Trial. - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02240472. Accessed June 25, 2022.
   Google Scholar
• Axillary node dissection versus no dissection in breast cancer with positive sentinel lymph node - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT01717131. Accessed June 25, 2022.
   Google Scholar
• POSNOC - A trial looking at axillary treatment in early breast cancer - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02401685. Accessed June 25, 2022.
   Google Scholar
• Regional radiotherapy in biomarker low-risk node positive and T3N0 breast cancer - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03488693. Accessed June 25, 2022.
   Google Scholar
• Standard or comprehensive radiation therapy in treating patients with early-stage breast cancer previously treated with chemotherapy and surgery - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT01872975. Accessed June 25, 2022.
   Google Scholar
• James R, McCulley SJ, Macmillan RD. Oncoplastic and reconstructive breast surgery in the elderly. Br J Surg. 2015;102(5):480–488. doi:10.1002/BJS.9733
   Web of Science ®Google Scholar
• Ritter M, Ling BM, Oberhauser I, et al. The impact of age on patient-reported outcomes after oncoplastic versus conventional breast cancer surgery. Breast Cancer Res Treat. 2021;187(2):437–446. doi:10.1007/S10549-021-06126-6
   Web of Science ®Google Scholar
• Lichtman SM, Cirrincione CT, Hurria A, et al. Effect of pretreatment renal function on treatment and clinical outcomes in the adjuvant treatment of older women with breast cancer: alliance A171201, an ancillary study of CALGB/CTSU 49907. J Clin Oncol. 2016;34(7):699–705. doi:10.1200/JCO.2015.62.6341
   PubMed Web of Science ®Google Scholar
• Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24(18):2750–2756. doi:10.1200/JCO.2005.02.3028
   Web of Science ®Google Scholar
• Tamirisa N, Lin H, Shen Y, et al. Association of chemotherapy with survival in elderly patients with multiple comorbidities and estrogen receptor-positive, node-positive breast cancer. JAMA Oncol. 2020;6(10):1548–1554. doi:10.1001/JAMAONCOL.2020.2388
   Web of Science ®Google Scholar
• Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006;24(18):2757–2764. doi:10.1200/JCO.2005.03.6053
   Web of Science ®Google Scholar
• Barcenas CH, Niu J, Zhang N, et al. Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol. 2014;32(19):2010–2017. doi:10.1200/JCO.2013.49.3676
   Web of Science ®Google Scholar
• Rosenstock AS, Lei X, Tripathy D, Hortobagyi GN, Giordano SH, Chavez-MacGregor M. Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer. Breast Cancer Res Treat. 2016;157(2):339–350. doi:10.1007/S10549-016-3815-Y
   Web of Science ®Google Scholar
• Muss HB, Polley MYC, Berry DA, et al. Randomized trial of standard adjuvant chemotherapy regimens versus capecitabine in older women with early breast cancer: 10-year update of the CALGB 49907 trial. J Clin Oncol. 2019;37(26):2338–2348. doi:10.1200/JCO.19.00647
   Web of Science ®Google Scholar
• Gralow JR, Barlow WE, Paterson AHG, et al. Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. J Natl Cancer Inst. 2020;112(7):698–707. doi:10.1093/JNCI/DJZ215
   Google Scholar
• Perrone F, Nuzzo F, Di Rella F, et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Ann Oncol. 2015;26(4):675–682. doi:10.1093/ANNONC/MDU564
   PubMed Web of Science ®Google Scholar
• Albain K, Anderson S, Arriagada R, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–444. doi:10.1016/S0140-6736(11)61625-5
   PubMed Web of Science ®Google Scholar
• Shulman LN, Berry DA, Cirrincione CT, et al. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014;32(22):2311–2317. doi:10.1200/JCO.2013.53.7142
   Web of Science ®Google Scholar
• Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25(25):3808–3815. doi:10.1200/JCO.2006.10.4976
   PubMed Web of Science ®Google Scholar
• Jones S, Holmes FA, O’Shaughnessy J, et al. Docetaxel with Cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and Cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol. 2009;27(8):1177–1183. doi:10.1200/JCO.2008.18.4028
   PubMed Web of Science ®Google Scholar
• Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in Early Breast Cancer: the ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017;35(23):2647–2655. doi:10.1200/JCO.2016.71.4147
   PubMed Web of Science ®Google Scholar
• Brouwers B, Hatse S, Dal Lago L, et al. The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. Oncotarget. 2016;7(21):29977. doi:10.18632/ONCOTARGET.8796
   Google Scholar
• Brollo J, Curigliano G, Disalvatore D, et al. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev. 2013;39(1):44–50. doi:10.1016/J.CTRV.2012.03.009
   PubMed Web of Science ®Google Scholar
• Sawaki M, Taira N, Uemura Y, et al. Randomized controlled trial of trastuzumab with or without chemotherapy for HER2-positive early breast cancer in older patients. J Clin Oncol. 2020;38(32):3743–3752. doi:10.1200/JCO.20.00184
   PubMed Web of Science ®Google Scholar
• Shenoy C, Klem I, Crowley AL, et al. Cardiovascular complications of breast cancer therapy in older adults. Oncologist. 2011;16(8):1138–1143. doi:10.1634/THEONCOLOGIST.2010-0348
   Web of Science ®Google Scholar
• Mackey JR, Martin M, Pienkowski T, et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the Phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013;14(1):72–80. doi:10.1016/S1470-2045(12)70525-9
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. New Engl J Med. 2015;372(2):134–141. doi:10.1056/NEJMOA1406281
   PubMed Web of Science ®Google Scholar
• Jones SE, Collea R, Paul D, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol. 2013;14(11):1121–1128. doi:10.1016/S1470-2045(13)70384-X
   PubMed Web of Science ®Google Scholar
• Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA. Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol. 2014;32(9):927–934. doi:10.1200/JCO.2013.51.1261
   PubMed Web of Science ®Google Scholar
• Chavez-MacGregor M, Zhang N, Buchholz TA, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013;31(33):4222–4228. doi:10.1200/JCO.2013.48.7884
   PubMed Web of Science ®Google Scholar
• Chavez-MacGregor M, Niu J, Zhang N, et al. Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older patients with breast cancer. J Clin Oncol. 2015;33(19):2176–2183. doi:10.1200/JCO.2014.58.9465
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. New Engl J Med. 2017;377(2):122–131. doi:10.1056/NEJMOA1703643/SUPPL_FILE/NEJMOA1703643_DISCLOSURES.PDF
   PubMed Web of Science ®Google Scholar
• Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367–377. doi:10.1016/S1470-2045(15)00551-3
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. New Engl J Med. 2019;380(7):617–628. doi:10.1056/NEJMOA1814017/SUPPL_FILE/NEJMOA1814017_DATA-SHARING.PDF
   PubMed Web of Science ®Google Scholar
• Stueber TN, Diessner J, Bartmann C, et al. Effect of adjuvant radiotherapy in elderly patients with breast cancer. PLoS One. 2020;15(5):e0229518. doi:10.1371/JOURNAL.PONE.0229518
   Web of Science ®Google Scholar
• Zureick AH, Grzywacz VP, Almahariq MF, et al. Dose to the left anterior descending artery correlates with cardiac events after irradiation for breast cancer. Int J Radiat Oncol Biol Phys. 2022;114(1):130–139. doi:10.1016/J.IJROBP.2022.04.019
   PubMed Web of Science ®Google Scholar
• Duma MN, Baumann R, Budach W, et al. Heart-sparing radiotherapy techniques in breast cancer patients: a recommendation of the breast cancer expert panel of the German society of radiation oncology (DEGRO). Strahlentherapie und Onkologie. 2019;195(10):861–871. doi:10.1007/S00066-019-01495-W
   PubMed Web of Science ®Google Scholar
• Offersen B, Alsner J, Nielsen HM, et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized Phase III Trial: the DBCG HYPO Trial. J Clin Oncol. 2020;38(31):3615–3636. doi:10.1200/JCO.20.01363
   PubMed Web of Science ®Google Scholar
• Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–520. doi:10.1056/NEJMOA0906260
   PubMed Web of Science ®Google Scholar
• Agrawal RK, Aird EGA, Barrett JM, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098–1107. doi:10.1016/S0140-6736(08)60348-7
   Web of Science ®Google Scholar
• Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613–1626. doi:10.1016/S0140-6736(20)30932-6
   PubMed Web of Science ®Google Scholar
• Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390(10099):1048–1060. doi:10.1016/S0140-6736(17)31145-5/ATTACHMENT/77605C63-0D13-49A4-979C-B2C6CFF18200/MMC1.PDF
   Web of Science ®Google Scholar
• Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet. 2019;394(10215):2165–2172. doi:10.1016/S0140-6736(19)32515-2
   PubMed Web of Science ®Google Scholar
• Meattini I, Marrazzo L, Saieva C, et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized Phase III APBI-IMRT-Florence Trial. J Clin Oncol. 2020;38(35):4175–4183. doi:10.1200/JCO.20.00650
   PubMed Web of Science ®Google Scholar
• Sumodhee S, Levy J, Chamorey E, et al. Accelerated partial breast irradiation for elderly women with early breast cancer: a compromise between whole breast irradiation and omission of radiotherapy. Brachytherapy. 2017;16(5):929–934. doi:10.1016/J.BRACHY.2017.06.006
   Web of Science ®Google Scholar
• Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–1716. doi:10.1016/S0140-6736(11)61629-2
   PubMed Web of Science ®Google Scholar
• Matuschek C, Bölke E, Haussmann J, et al. The benefit of adjuvant radiotherapy after breast conserving surgery in older patients with low risk breast cancer- a meta-analysis of randomized trials. Radiat Oncol. 2017;12(1). doi:10.1186/S13014-017-0796-X
   Web of Science ®Google Scholar
• Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382–2387. doi:10.1200/JCO.2012.45.2615
   PubMed Web of Science ®Google Scholar
• Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16(3):266–273. doi:10.1016/S1470-2045(14)71221-5
   PubMed Web of Science ®Google Scholar
• Nikyar N, Tegnelius E, Valachis A. Adjuvant locoregional radiation therapy in breast cancer patients with pathologic complete response after neoadjuvant chemotherapy: a systematic review and meta-analysis. Clin Transl Radiat Oncol. 2022;33:45–52. doi:10.1016/J.CTRO.2021.12.010
   Web of Science ®Google Scholar
• Mandish SF, Gaskins JT, Yusuf MB, Amer YM, Eldredge-Hindy H. The effect of omission of adjuvant radiotherapy after neoadjuvant chemotherapy and breast conserving surgery with a pathologic complete response. Acta Oncol. 2020;59(10):1210–1217. doi:10.1080/0284186X.2020.1797161
   PubMed Web of Science ®Google Scholar
• Tramm T, Mohammed H, Myhre S, et al. Development and validation of a gene profile predicting benefit of postmastectomy radiotherapy in patients with high-risk breast cancer: a study of gene expression in the DBCG82bc cohort. Clin Cancer Res. 2014;20(20):5272–5280. doi:10.1158/1078-0432.CCR-14-0458
   PubMed Web of Science ®Google Scholar
• Speers C, Chang SL, Pesch A, et al. A signature that may be predictive of early versus late recurrence after radiation treatment for breast cancer that may inform the biology of early, aggressive recurrences. Int J Radiat Oncol Biol Phys. 2020;108(3):686–696. doi:10.1016/J.IJROBP.2020.05.015
   Web of Science ®Google Scholar
• Torres-Roca JF, Fulp WJ, Caudell JJ, et al. Integration of a radiosensitivity molecular signature into the assessment of local recurrence risk in breast cancer. Int J Radiat Oncol Biol Phys. 2015;93(3):631–638. doi:10.1016/J.IJROBP.2015.06.021
   Web of Science ®Google Scholar
• Eschrich SA, Fulp WJ, Pawitan Y, et al. Validation of a radiosensitivity molecular signature in breast cancer. Clin Cancer Res. 2012;18(18):5134–5143. doi:10.1158/1078-0432.CCR-12-0891
   PubMed Web of Science ®Google Scholar
• Ahmed KA, Liveringhouse CL, Mills MN, et al. Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management. EBioMedicine. 2019;47:163–169. doi:10.1016/J.EBIOM.2019.08.019
   Web of Science ®Google Scholar
• Rakovitch E, Nofech-Mozes S, Hanna W, et al. Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in situ. J Natl Cancer Inst. 2017;109:4. doi:10.1093/JNCI/DJW256
   Google Scholar
• Bremer T, Whitworth PW, Patel R, et al. A biological signature for breast ductal carcinoma in situ to predict radiotherapy benefit and assess recurrence risk. Clin Cancer Res. 2018;24(23):5895–5901. doi:10.1158/1078-0432.CCR-18-0842
   PubMed Web of Science ®Google Scholar
• The IDEA Study (Individualized Decisions for Endocrine Therapy Alone) - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02400190. Accessed June 25, 2022.
   Google Scholar
• A prospective cohort study evaluating risk of local recurrence following breast conserving surgery and endocrine therapy in low risk luminal a breast cancer - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT01791829. Accessed June 25, 2022.
   Google Scholar
• The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): a Phase II study of breast-conserving surgery without adjuvant radiotherapy for favorable-risk breast cancer - Full Text View - ClinicalTrials.gov. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02653755. Accessed June 25, 2022.
   Google Scholar
• Murphy CT, Li T, Wang LS, et al. Comparison of adjuvant radiation therapy alone versus radiation therapy and endocrine therapy in elderly women with early-stage, hormone receptor-positive breast cancer treated with breast-conserving surgery. Clin Breast Cancer. 2015;15(5):381–389. doi:10.1016/J.CLBC.2015.02.005
   Web of Science ®Google Scholar
• Jeon YW, You SH, Lee JE, et al. Optimal treatment of breast cancer in women older than 75 years: a Korea Breast Cancer Registry analysis. Breast Cancer Res Treat. 2019;178(3):693. doi:10.1007/S10549-019-05426-2
   Web of Science ®Google Scholar
• Crystal JS, Rand J, Johnson J, et al. Adjuvant endocrine therapy is associated with improved overall survival in elderly hormone receptor-positive breast cancer patients. Breast Cancer Res Treat. 2020;184(1):63–74. doi:10.1007/S10549-020-05823-Y
   Web of Science ®Google Scholar
• Khan AJ, Parikh RR, Neboori HJ, Goyal S, Haffty BG, Moran MS. The relative benefits of tamoxifen in older women with T1 early-stage breast cancer treated with breast-conserving surgery and radiation therapy. Breast J. 2013;19(5):490–495. doi:10.1111/TBJ.12150
   Web of Science ®Google Scholar
• Meneveau MO, Keim-Malpass J, Camacho TF, Anderson RT, Showalter SL. Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer. Breast Cancer Res Treat. 2020;184(3):805–816. doi:10.1007/S10549-020-05908-8
   Web of Science ®Google Scholar
• Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001;12(11):1527–1532.
   PubMed Web of Science ®Google Scholar
• Miller WR, Dixon JM, Cameron DA, Anderson TJ. Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J Steroid Biochem Mol Biol. 2001;79(1–5):103–107. doi:10.1016/S0960-0760(01)00149-2
   Web of Science ®Google Scholar
• Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial - PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/17695434/. Accessed June 25, 2022.
   Google Scholar
• Madigan LI, Dinh P, Graham JD. Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines. Breast Cancer Res. 2020;22(1). doi:10.1186/S13058-020-01314-6
   Web of Science ®Google Scholar
• Barchiesi G, Mazzotta M, Krasniqi E, et al. Neoadjuvant endocrine therapy in breast cancer: current knowledge and future perspectives. Int J Mol Sci. 2020;21(10):3528. doi:10.3390/IJMS21103528
   Web of Science ®Google Scholar
• Kantor O, Pesce C, Liederbach E, Wang CH, Winchester DJ, Yao K. Surgery and hormone therapy trends in octogenarians with invasive breast cancer. Am J Surg. 2016;211(3):541–545. doi:10.1016/J.AMJSURG.2015.11.005
   Web of Science ®Google Scholar
• Hind D, Wyld L, Reed MW. Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: cochrane review. Br J Cancer. 2007;96(7):1025. doi:10.1038/SJ.BJC.6603600
   PubMed Web of Science ®Google Scholar
• Pepping RMC, Portielje JEA, van de Water W, de Glas NA. Primary endocrine therapy in older women with breast cancer. Curr Geriatr Rep. 2017;6(4):239–246. doi:10.1007/S13670-017-0223-Z
   Web of Science ®Google Scholar
• Johnston SJ, Cheung KL. The role of primary endocrine therapy in older women with operable breast cancer. Future Oncol. 2015;11(10):1555–1565. doi:10.2217/FON.15.13
   Web of Science ®Google Scholar
• Morgan JL, Collins K, Robinson TG, et al. Healthcare professionals’ preferences for surgery or primary endocrine therapy to treat older women with operable breast cancer. Eur J Surg Oncol. 2015;41(9):1234–1242. doi:10.1016/J.EJSO.2015.05.022
   Web of Science ®Google Scholar
• Cheung WY, Lai ECC, Ruan JY, Chang JT, Setoguchi S. Comparative adherence to oral hormonal agents in older women with breast cancer. Breast Cancer Res Treat. 2015;152(2):419–427. doi:10.1007/S10549-015-3455-7
   Web of Science ®Google Scholar
• Marinopoulos S, Dimitrakakis C, Kalampalikis A, Zagouri F, Andrikopoulou A, Rodolakis A. Adjuvant treatment of elderly breast cancer patients: offer the best chances of cure. Breast Care. 2022;17(1):71–80. doi:10.1159/000513708
   Web of Science ®Google Scholar
• Yuan C, Xie Z, Bian J, Huo J, Daily K. Outcomes of primary endocrine therapy in elderly women with stage I-III breast cancer: a SEER database analysis. Breast Cancer Res Treat. 2020;180(3):819–827. doi:10.1007/S10549-020-05591-9
   Web of Science ®Google Scholar
• Poorvu PD, Vaz-Luis I, Freedman RA, et al. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States. Breast Cancer Res Treat. 2018;168(3):727–737. doi:10.1007/S10549-018-4659-4
   Web of Science ®Google Scholar
• Aapro M, Monfardini S, Jirillo A, Basso U. Management of primary and advanced breast cancer in older unfit patients (medical treatment). Cancer Treat Rev. 2009;35(6):503–508. doi:10.1016/J.CTRV.2009.04.002
   Web of Science ®Google Scholar
• Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2009;2009(2). doi:10.1002/14651858.CD003372.PUB3
   Web of Science ®Google Scholar
• Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol. 2005;23(10):2155–2161. doi:10.1200/JCO.2005.02.167
   PubMed Web of Science ®Google Scholar
• Vogel CL, O’Rourke M, Winer E, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol. 1999;10(4):397–402. doi:10.1023/A:1008364222793
   Web of Science ®Google Scholar
• Barni S, Livraghi L, Gravina A, et al. Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: a post-hoc analysis of the ESEMPiO study. J Geriatr Oncol. 2019;10(6):990–993. doi:10.1016/J.JGO.2019.05.003
   Web of Science ®Google Scholar
• Beuselinck B, Wildiers H, Wynendaele W, Dirix L, Kains JP, Paridaens R. Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology. Crit Rev Oncol Hematol. 2010;75(1):70–77. doi:10.1016/J.CRITREVONC.2009.07.001
   Web of Science ®Google Scholar
• O’Brien MER, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440–449. doi:10.1093/ANNONC/MDH097
   PubMed Web of Science ®Google Scholar
• Biganzoli L, Coleman R, Minisini A, et al. A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. Crit Rev Oncol Hematol. 2007;61(1):84–89. doi:10.1016/J.CRITREVONC.2006.07.008
   Web of Science ®Google Scholar
• Coleman RE, Biganzoli L, Canney P, et al. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer. 2006;42(7):882–887. doi:10.1016/J.EJCA.2005.12.011
   Web of Science ®Google Scholar
• Kaufman PA, Brufsky AM, Mayer M, et al. Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat. 2012;135(3):875. doi:10.1007/S10549-012-2209-Z
   PubMed Web of Science ®Google Scholar
• Wildiers H, Tryfonidis K, Dal Lago L, et al. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet Oncol. 2018;19(3):323–336. doi:10.1016/S1470-2045(18)30083-4
   PubMed Web of Science ®Google Scholar
• Freedman RA, Tolaney SM. Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review. Breast Cancer Res Treat. 2018;167(3):607–614. doi:10.1007/S10549-017-4560-6
   Web of Science ®Google Scholar
• Howie LJ, Singh H, Bloomquist E, et al. Outcomes of older women with hormone receptor-positive, human epidermal growth factor receptor-negative metastatic breast cancer treated with a CDK4/6 inhibitor and an aromatase inhibitor: an FDA pooled analysis. J Clin Oncol. 2019;37(36):3475–3483. doi:10.1200/JCO.18.02217
   PubMed Web of Science ®Google Scholar
• Rugo HS, Turner NC, Finn RS, et al. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Eur J Cancer. 2018;101:123–133. doi:10.1016/J.EJCA.2018.05.017
   PubMed Web of Science ®Google Scholar
• Cazzaniga M, Verusio C, Ciccarese M, et al. Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study. Oncotarget. 2018;9(61):31877. doi:10.18632/ONCOTARGET.25874
   Google Scholar
• Pritchard KI, Burris HA, Ito Y, et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer. 2013;13(6):421–432.e8. doi:10.1016/J.CLBC.2013.08.011
   PubMed Web of Science ®Google Scholar
• Almodallal Y, Le-Rademacher JG, Cook KD, et al. Observations with alpelisib in older patients (≥ 65 year of age) with breast cancer in a non-clinical trial setting. Breast Cancer Res Treat. 2021;188(1):15–20. doi:10.1007/S10549-021-06277-6
   Web of Science ®Google Scholar